JP2016510989A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510989A5
JP2016510989A5 JP2015562528A JP2015562528A JP2016510989A5 JP 2016510989 A5 JP2016510989 A5 JP 2016510989A5 JP 2015562528 A JP2015562528 A JP 2015562528A JP 2015562528 A JP2015562528 A JP 2015562528A JP 2016510989 A5 JP2016510989 A5 JP 2016510989A5
Authority
JP
Japan
Prior art keywords
vector
administration
poxvirus
nucleic acid
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015562528A
Other languages
English (en)
Japanese (ja)
Other versions
JP6702725B2 (ja
JP2016510989A (ja
Filing date
Publication date
Priority claimed from PCT/EP2013/055409 external-priority patent/WO2014139587A1/en
Application filed filed Critical
Publication of JP2016510989A publication Critical patent/JP2016510989A/ja
Publication of JP2016510989A5 publication Critical patent/JP2016510989A5/ja
Application granted granted Critical
Publication of JP6702725B2 publication Critical patent/JP6702725B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015562528A 2013-03-15 2014-03-14 改良されたポックスウイルスワクチン Expired - Fee Related JP6702725B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2013/055409 2013-03-15
PCT/EP2013/055409 WO2014139587A1 (en) 2013-03-15 2013-03-15 Improved poxviral vaccines
PCT/IB2014/059802 WO2014141176A1 (en) 2013-03-15 2014-03-14 Improved poxviral vaccines

Publications (3)

Publication Number Publication Date
JP2016510989A JP2016510989A (ja) 2016-04-14
JP2016510989A5 true JP2016510989A5 (https=) 2017-04-13
JP6702725B2 JP6702725B2 (ja) 2020-06-03

Family

ID=47882194

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562528A Expired - Fee Related JP6702725B2 (ja) 2013-03-15 2014-03-14 改良されたポックスウイルスワクチン

Country Status (17)

Country Link
US (3) US20160000904A1 (https=)
EP (1) EP2968493B1 (https=)
JP (1) JP6702725B2 (https=)
CN (2) CN109182378A (https=)
BE (1) BE1021192B1 (https=)
BR (1) BR112015023524B1 (https=)
CA (1) CA2907026A1 (https=)
CY (1) CY1120740T1 (https=)
DK (1) DK2968493T3 (https=)
ES (1) ES2685922T3 (https=)
HR (1) HRP20181376T1 (https=)
HU (1) HUE040189T2 (https=)
LT (1) LT2968493T (https=)
PL (1) PL2968493T3 (https=)
PT (1) PT2968493T (https=)
SI (1) SI2968493T1 (https=)
WO (2) WO2014139587A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10576143B2 (en) 2013-03-15 2020-03-03 Glaxosmithkline Biologicals Sa Poxviral vaccines
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
GB201321384D0 (en) * 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
WO2017025782A1 (en) * 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
KR20180004820A (ko) 2015-05-15 2018-01-12 큐어백 아게 적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법
MX2019002178A (es) * 2016-08-23 2019-09-18 Glaxosmithkline Biologicals Sa Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
GB201704417D0 (en) 2017-03-20 2017-05-03 Univ Copenhagen Improved li vaccine adjuvant
JP7298926B2 (ja) * 2017-07-12 2023-06-27 ノイスコム アーゲー 癌の治療のためのネオアンチゲンワクチン組成物
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201812647D0 (en) * 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
EP3897846A1 (en) * 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
TW202102256A (zh) 2019-03-05 2021-01-16 比利時商葛蘭素史密斯克藍生物品公司 B型肝炎免疫法及組合物
CN111057716B (zh) * 2019-07-27 2022-04-15 中国人民解放军军事科学院军事医学研究院 用于包装重组人4型腺病毒的单质粒载体系统及其应用
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1272179B (it) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
CA2461380C (en) 2001-10-11 2011-03-22 Merck & Co., Inc. Hepatitis c virus vaccine
CN102703393A (zh) * 2002-05-16 2012-10-03 巴法里安诺迪克有限公司 表达插入痘病毒基因组中的同源基因的重组痘病毒
ATE449105T1 (de) 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
EP1957528B1 (en) 2005-11-30 2012-11-07 University of Copenhagen A nucleotide vaccine
HUE045093T2 (hu) * 2008-11-21 2019-12-30 Kobenhavns Univ University Of Copenhagen Immunválasz kiváltása
EP2391638B1 (en) 2009-02-02 2018-06-27 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
US10576143B2 (en) * 2013-03-15 2020-03-03 Glaxosmithkline Biologicals Sa Poxviral vaccines
GB201321384D0 (en) 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
MX2019002178A (es) 2016-08-23 2019-09-18 Glaxosmithkline Biologicals Sa Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).

Similar Documents

Publication Publication Date Title
JP2016510989A5 (https=)
ES2800623T3 (es) Promotor PR13.5 para respuestas contundentes de células T y anticuerpos
Herbert et al. Recombinant adenovirus expressing the haemagglutinin of peste des petits ruminants virus (PPRV) protects goats against challenge with pathogenic virus; a DIVA vaccine for PPR
Verardi et al. A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication
EP1616954B1 (en) Methods and reagents for vaccination which generate a CD8+ Tcell immune response against hepatitis B or C
Schneider et al. Induction of CD8+ T cells using heterologous prime‐boost immunisation strategies
MX2022009962A (es) Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2.
JP2014503206A5 (https=)
JP2015533841A5 (https=)
AU2002347317B2 (en) Vaccine
US20160304582A1 (en) Molecular adjuvant
JP2020516264A5 (https=)
JP2013507907A5 (https=)
SG10201901735XA (en) Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
CA3067405A1 (en) Personalized vaccine comprising a recombinant poxvirus expressing a fusioin of nepopeptides
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
RU2019107976A (ru) Композиция вакцины
JP6851364B2 (ja) ポックスウイルスにおける発現を増強するためのプロモーター
JP2016510989A (ja) 改良されたポックスウイルスワクチン
JP2012515557A5 (https=)
EA201890042A1 (ru) Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
JP2017527568A (ja) フィロウイルス感染に対する防御免疫の誘導を目的とする方法及び組成物
JP2017503479A (ja) ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター
JP2018521651A5 (https=)
JP2016074727A5 (https=)